TLK286 (Telcyta) in Combination With Cisplatin for Locally Advanced or Metastatic Non-small Cell Lung Cancer (NSCLC)

Phase 1-2a Dose-Ranging Study of TLK286 in Combination With Cisplatin as First-Line Therapy in Locally Advanced or Metastatic Non-Small Cell Lung Cancer

The purpose of this trial is to study the efficacy and safety of the combination of TLK286 with cisplatin as first-line therapy for patients with locally advanced or metastatic non-small cell lung cancer.

Inclusion Criteria:

• 18 years of age or older
• Histologically confirmed non-small cell lung cancer
• Stage IV or IIIB
• Measurable disease by RECIST
• ECOG performance status of 0-1
• Adequate liver and renal function
• Adequate bone marrow reserve

Exclusion Criteria:

• History of bone marrow transplantation or stem cell support
• Pregnant or lactating women